- Source:
Publisher: American Physiological Society Country of Publication: United States NLM ID: 8502536 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1522-1601 (Electronic) Linking ISSN: 01617567 NLM ISO Abbreviation: J Appl Physiol (1985) Subsets: MEDLINE
- Publication Information:
Original Publication: Bethesda, MD : American Physiological Society, c1985-
- Subject Terms:
- Abstract:
Ultramarathon participation is growing in popularity and exposes runners to unique stressors including extreme temperatures, high altitude, and exceedingly long exercise duration. However, the acute effects of ultramarathon participation on the cardiovascular system are not well understood. To determine the acute effects of trail ultramarathon participation on central artery stiffness and hemodynamics, 41 participants (9 F, 32 M) participating in the 2023 Western States Endurance Run underwent measures of carotid-femoral pulse wave velocity (cf-PWV) and pulse wave analysis pre- and <1 h post-race. Subendocardial viability ratio (SEVR) was calculated from central blood pressure (BP) waveforms. Serum was analyzed for creatine kinase (CK) activity as a measure of muscle damage. Normally distributed data are presented as means ± standard deviation (SD), and nonnormally distributed data are presented as median (interquartile range). Runners were middle-aged and generally lean [age = 44 ± 9 yr, body mass index (BMI) = 22.7 ± 1.8 kg·m -2 ]. There was no difference in cf-PWV from pre- to post-race (pre = 6.4 ± 1.0, post = 6.2 ± 0.85 m/s, P = 0.104), a finding that persisted after adjusting for mean arterial pressure ( P = 0.563). Systolic and diastolic BPs were lower post-race (pre = 129/77 ± 9/7, post = 122/74 ± 10/8 mmHg, P < 0.001). Augmentation index (AIx; pre = 17.3 ± 12.2, post = 6.0 ± 13.7%, P < 0.001), AIx normalized to a heart rate of 75 beats/min ( P = 0.043), reflection magnitude (pre = 55.5(49.0-60.8), post = 45.5(41.8-48.8)%, P < 0.001), and SEVR (pre = 173.0(158.0-190.0), post = 127.5(116.5-145.8)%, P < 0.001) were reduced post-race. CK increased markedly from pre- to post-race (pre = 111(85-162), post = 11,973(5,049-17,954) U/L, P < 0.001). Completing a 161-km trail ultramarathon does not affect central arterial stiffness and acutely reduces BP despite eliciting profound muscle damage. However, the reduced post-race SEVR suggests a short-term mismatch between myocardial work and coronary artery perfusion. NEW AND NOTEWORTHY Ultramarathon participation is growing dramatically. However, the acute cardiovascular effects of completing a 161-km trail ultramarathon remain unknown. We examined the acute effects of completing the 2023 Western States Endurance Run on arterial stiffness and central hemodynamics in a relatively large sample of males and females. We observed dramatic postexercise hypotension, reductions in reflected wave amplitude and reduced subendocardial viability ratio post-race. These findings suggest that ultramarathon participation has few negative effects on cardiovascular health.
- References:
Clin Physiol Funct Imaging. 2018 May;38(3):447-454. (PMID: 28444935)
Nutrients. 2019 Aug 11;11(8):. (PMID: 31405195)
Exp Physiol. 2013 Jan;98(1):7-18. (PMID: 22872658)
Nitric Oxide. 2016 Jan 30;52:49-55. (PMID: 26679695)
Circulation. 2005 Oct 4;112(14):2193-200. (PMID: 16186422)
Eur Heart J. 2013 Jun;34(24):1790-9. (PMID: 23569199)
Hypertension. 2006 Jun;47(6):1203-8. (PMID: 16651459)
Annu Int Conf IEEE Eng Med Biol Soc. 2012;2012:2591-4. (PMID: 23366455)
J Appl Physiol (1985). 2017 Apr 1;122(4):925-932. (PMID: 28153943)
Hypertension. 2009 Aug;54(2):375-83. (PMID: 19564542)
Clin J Sport Med. 2018 Nov;28(6):509-515. (PMID: 29189337)
PLoS One. 2022 Sep 1;17(9):e0273510. (PMID: 36048789)
Sports (Basel). 2017 Jan 29;5(1):. (PMID: 29910371)
Front Physiol. 2015 Jul 22;6:204. (PMID: 26257656)
J Am Soc Echocardiogr. 2016 Apr;29(4):277-314. (PMID: 27037982)
Circulation. 2020 Mar 31;141(13):e705-e736. (PMID: 32100573)
J Appl Physiol. 1974 Nov;37(5):695-8. (PMID: 4436195)
Med Sci Sports Exerc. 2022 Oct 1;54(10):1647-1656. (PMID: 35653262)
Curr Treat Options Cardiovasc Med. 2018 Aug 28;20(10):84. (PMID: 30155804)
Am J Hypertens. 2010 Sep;23(9):974-9. (PMID: 20489686)
Am J Physiol. 1969 Dec;217(6):1644-51. (PMID: 5353039)
Am J Physiol. 1958 Jan;192(1):148-56. (PMID: 13498167)
Biol Sport. 2015 Dec;32(4):357-361. (PMID: 28479667)
Wilderness Environ Med. 2023 Jun;34(2):218-221. (PMID: 36805094)
J Am Heart Assoc. 2024 Mar 19;13(6):e032614. (PMID: 38471822)
Circulation. 2024 Oct;150(14):1075-1086. (PMID: 39166326)
Med Sci Sports Exerc. 2020 Apr;52(4):935-943. (PMID: 31609296)
Med Sci Sports Exerc. 1995 Dec;27(12):1595-601. (PMID: 8614313)
Hypertension. 2019 May;73(5):1025-1035. (PMID: 30905199)
Med Sci Sports Exerc. 2001 Nov;33(11):1855-61. (PMID: 11689735)
Int J Sports Med. 2012 Mar;33(3):224-9. (PMID: 22261822)
Exp Physiol. 2024 Aug;109(8):1385-1394. (PMID: 38860912)
Hypertens Res. 2013 Mar;36(3):226-31. (PMID: 23051656)
Br Med Bull. 2007;81-82:209-30. (PMID: 17569697)
Circulation. 1991 May;83(5):1557-61. (PMID: 2022015)
Eur Heart J. 2013 Mar;34(10):759-66. (PMID: 22711752)
J Appl Physiol (1985). 2010 Oct;109(4):1102-8. (PMID: 20671032)
J Nutr Metab. 2012;2012:960363. (PMID: 22288008)
J Am Coll Cardiol. 2010 Mar 30;55(13):1318-27. (PMID: 20338492)
J Sci Med Sport. 2015 Mar;18(2):230-5. (PMID: 24709362)
Am J Physiol. 1994 Oct;267(4 Pt 2):H1368-76. (PMID: 7943382)
Eur J Appl Physiol. 2018 Mar;118(3):523-530. (PMID: 29234916)
Med Sci Sports Exerc. 2021 Mar 1;53(3):597-605. (PMID: 32804900)
J Sci Med Sport. 2014 May;17(3):322-5. (PMID: 23707138)
Am J Cardiol. 2012 Jul 1;110(1):45-9. (PMID: 22463837)
Emerg Med J. 2017 Oct;34(10):637-642. (PMID: 28679502)
Clin J Sport Med. 2013 Jan;23(1):58-63. (PMID: 22673537)
Hypertension. 2016 Nov;68(5):1290-1297. (PMID: 27672029)
Sports Med. 2006;36(5):429-41. (PMID: 16646630)
Front Physiol. 2018 Feb 13;9:73. (PMID: 29487535)
Hypertension. 2001 Oct;38(4):932-7. (PMID: 11641312)
J Clin Med. 2022 Jul 02;11(13):. (PMID: 35807128)
Lancet. 1953 Nov 21;262(6795):1053-1057. (PMID: 13110049)
Redox Biol. 2023 Jul;63:102718. (PMID: 37120928)
Lancet. 2017 Dec 16;390(10113):2643-2654. (PMID: 28943267)
Yale J Biol Med. 1980 Jul-Aug;53(4):275-9. (PMID: 7445533)
Am J Hypertens. 2008 Oct;21(10):1100-6. (PMID: 18719622)
J Am Soc Hypertens. 2014 Jun;8(6):388-93. (PMID: 24794204)
Med Sci Sports Exerc. 2012 Sep;44(9):1644-52. (PMID: 22899388)
Circ Res. 1972 Jan;30(1):67-81. (PMID: 5007529)
Exerc Sport Sci Rev. 2001 Oct;29(4):159-63. (PMID: 11688788)
J Cardiovasc Pharmacol Ther. 2001 Jan;6(1):5-21. (PMID: 11452332)
Phys Sportsmed. 2017 May;45(2):129-133. (PMID: 28075653)
Circulation. 2011 Aug 16;124(7):789-95. (PMID: 21810663)
Circ Res. 1962 Sep;11:370-80. (PMID: 13981593)
Int J Cardiol. 2007 Jan 2;114(1):50-6. (PMID: 16675046)
J Am Soc Echocardiogr. 2019 Jan;32(1):1-64. (PMID: 30282592)
- Grant Information:
K01 HL147998 United States HL NHLBI NIH HHS; UL1TR003096 HHS | NIH | National Center for Advancing Translational Sciences (NCATS); K01HL147998 HHS | NIH | National Heart, Lung, and Blood Institute (NHLBI); U54AG062319 HHS | NIH | National Institute on Aging (NIA); L30 HL154374 United States HL NHLBI NIH HHS; K01HL160772 HHS | NIH | National Heart, Lung, and Blood Institute (NHLBI); Western States Endurance Run Medical Research Foundation; 23CDA1037938 American Heart Association (AHA); R15HL165325 HHS | NIH | National Heart, Lung, and Blood Institute (NHLBI); K01HL164978 HHS | NIH | National Heart, Lung, and Blood Institute (NHLBI)
- Contributed Indexing:
Keywords: arterial stiffness; central hemodynamics; exercise physiology; pulse wave analysis; ultramarathon
- Accession Number:
EC 2.7.3.2 (Creatine Kinase)
- Publication Date:
Date Created: 20240919 Date Completed: 20241105 Latest Revision: 20241116
- Publication Date:
20241116
- Accession Number:
PMC11563584
- Accession Number:
10.1152/japplphysiol.00412.2024
- Accession Number:
39298619
Processing Request
No Comments.